Entries |
Document | Title | Date |
20100240580 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF - The invention relates to azoloarine derivatives of formula I | 09-23-2010 |
20100249024 | CETP INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A | 09-30-2010 |
20100261644 | (CYCLOPROPYLPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT - The invention relates to (cyclopropylphenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament. | 10-14-2010 |
20100261645 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT - The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament. | 10-14-2010 |
20100292140 | ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 4 EXPRESSION - Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided. | 11-18-2010 |
20100292141 | INSULIN NASAL POWDER INHALATION - An inhalable nasal powder preparation of insulin and its preparing process are provided. The powder inhalation is consisting of self-emulsifying freeze-dried powder and pharmaceutically acceptable carriers. The dry powder comprises insulin, fat(s), emulsifier(s), antioxidant(s), supporting agent(s), bio-gel adhesive(s), and pH modifier(s), wherein the emulsifier is a mixture of lecithin and Tween 80, and the amount of fat in the formulation is determined by the surface area and the particle diameter of oil droplet. | 11-18-2010 |
20100317575 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE - The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim | 12-16-2010 |
20110003740 | INSULIN SENSITISERS AND METHODS OF TREATMENT - The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods. | 01-06-2011 |
20110034378 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. - The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R | 02-10-2011 |
20110065634 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE - The present invention relates to compounds of general formula (I), wherein ring A, ring B, R | 03-17-2011 |
20110098220 | METHODS AND KITS FOR PREVENTING HYPOGLYCEMIA - The present invention provides improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy. | 04-28-2011 |
20110105393 | METHODS FOR PROMOTING STEM CELL PROLIFERATION AND SURVIVAL - Methods are disclosed herein for increasing the number of stem cells or precursor cells. The number of stem cells can be increased by increasing survival and/or cell proliferation of the cells. The methods include contacting the cells with an effective amount of a Notch ligand, an effective amount of a growth factor, and an effective amount of angiopoietin-2 (Ang-2). In several embodiments, the methods include contacting the cells with an effective amount of a Jak inhibitor. In several non-limiting examples, the growth factor is insulin or glial derived neurotrophic factor (GDNF), or a combination thereof. In additional non-limiting examples, the Notch ligand is Delta. The cells can be in vivo or in vitro. Methods are also disclosed here for the treatment of a neurodegenerative disorder or spinal cord injury in a subject. In several non-limiting examples, the subject has Parkinson's disease or Alzheimer's disease. | 05-05-2011 |
20110144011 | Cellular Activation Insulin Therapy - Diabetic and other patients are treated using an aggressive form of Pulsed Insulin Therapy in which a pre-treatment blood sugar level in the patient of at least 250-300 mg/dL, and the patient is treated with at least first and second cycles, each cycle comprising (1) pulsing a recombinant human insulin to the patient in concentrations of more than 10% to achieve a target intra-treatment blood sugar level (BSL) swing of more than 100 mg/dL, and (2) raising the blood sugar level to at least 250-300 mg/dL. | 06-16-2011 |
20110152185 | Pharmaceutical Compositions Comprising GLP-1 Peptides or Extendin-4 and a Basal Insulin Peptide - Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules. | 06-23-2011 |
20110166065 | MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION - Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders. | 07-07-2011 |
20110183901 | Superior Control of Blood Glucose in Diabetes Treatment - Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin. | 07-28-2011 |
20110218142 | Inhibitors of Dipeptidylpeptidase IV - The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of sidechains in the P1 and/or P2 position of the inhibitor that contain a carboxylic acid moiety. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 09-08-2011 |
20110230403 | GLYCOSIDE DERIVATIVES AND USES THEREOF - The present invention relates to compounds of formula I | 09-22-2011 |
20110237505 | Compositions and Methods for Treating Obesity and Diabetes - Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal. | 09-29-2011 |
20110263494 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF - Disclosed are compounds of Formula (I) wherein: one of A and D is —N— and the other of A and D is —C—; or enantiomers, diastereomers, or pharmaceutically-acceptable salts thereof. Also disclosed are methods of using such compounds to modulate the function of glucocorticoid receptor activity and pharmaceutical compositions comprising such compounds. | 10-27-2011 |
20110269679 | INHIBITORS OF AMYLOID FIBRIL FORMATION AND USES THEREOF - The present invention provides new antifibrillogenic agents and peptides, compositions and cells containing same, compositions that bind to same, effective therapeutics for preventing or delaying the progression of, e.g., Alzheimer's disease and diabetes, methods for optimizing antifibrillogenic agents, and methods of using the antifibrillogenic agents, peptides, compositions, and cells of the invention for detecting and/or inhibiting amyloid fibril formation. | 11-03-2011 |
20110275561 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug. | 11-10-2011 |
20110281795 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 11-17-2011 |
20110288014 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND PREVENTION - The present invention relates to methods and compositions for preventing or treating diabetes. The invention in particular discloses compounds according to formula (I) for use in the prevention and treatment of type II or I diabetes. | 11-24-2011 |
20110294730 | METHOD OF TREATING GLAUCOMA AND INTRAOCULAR HYPERTENSION - A safe and effective treatment for glaucoma for mammalian species comprises the steps of applying insulin and/or insulin like growth factors (IGF-1) to an eye. In addition to the insulin, another therapeutic agent may be applied to enhance the activity of the insulin. The therapeutic agent may be a pharmaceutical agent or a biochemical pharmaceutical agent. The therapeutic agents include prostaglandin analogs, topical beta-adrenergic receptor antagonists-β blockers, Alpha2-adrenergic agonists hair growth therapeutic agents, beta2-agonist action agents, parasympathomimetic miotic agents, carbonic anhydrase inhibitors, and Physostigmine. In another embodiment, a combination of at least two agents are applied to the eye. To enhance the effect of the insulin, uptake facilitators may be used. Additionally, an antibacterial agent may be applied to control bacterial infection. | 12-01-2011 |
20110301081 | LONG-ACTING FORMULATIONS OF INSULINS - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 12-08-2011 |
20110301082 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 12-08-2011 |
20110312882 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES - Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine. | 12-22-2011 |
20110319324 | METHODS OF AND COMPOSITIONS FOR STIMULATION OF GLUCOSE UPTAKE INTO MUSCLE CELLS AND TREATMENT OF DISEASES - The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity. | 12-29-2011 |
20110319325 | MULTI-COMPONENT PHARMACEUTICALS FOR TREATING DIABETES - Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat diabetes, and methods for preparing activated fatty acids are provided herein. | 12-29-2011 |
20110319326 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS - The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R | 12-29-2011 |
20120004165 | HETEROCYCLICALLY SUBSTITUTED METHOXYPHENYL DERIVATIVES WITH AN OXO GROUP, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS - Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments | 01-05-2012 |
20120004166 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT - The invention relates to aryloxyalkylene-substituted hydroxyphenylhexynoic acid derivatives, and to physiologically compatible salts thereof. | 01-05-2012 |
20120004167 | (2-ARYLOXYACETYLAMINO) PHENYLPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS - The invention relates to substituted (2-aryloxyacetylamino)phenylpropionic acid derivatives, and to the physiologically acceptable salts thereof. | 01-05-2012 |
20120010135 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE - The present invention provides spiro derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 01-12-2012 |
20120028892 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF - The invention is directed to a compound according to formula (I). The compounds of formula (I) include prodrugs, pharmaceutically acceptable salts, stereoisomer mixtures, and enantiomers thereof. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier and to methods for treating diabetes by administering such a pharmaceutical composition alone or in combination with other therapeutic agents. The invention is also directed to inhibitors of fructose-1,6-bisphosphatase. | 02-02-2012 |
20120035105 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments - The present invention includes a pharmaceutical composition comprising HDV insulin or oral HDV insulin, and one or more additional therapeutic agents useful for the treatment of diabetes and diabetes related ailments. The present invention also includes a method of making the pharmaceutical inventions of the application. The present invention further includes methods of treating diabetes and/or diabetes related ailments comprising administering a pharmaceutical composition of the invention to a patient in need thereof. The present invention also includes methods of treating diabetes related ailments comprising administering a pharmaceutical formulation of HDV insulin or a pharmaceutical formulation of oral HDV insulin. | 02-09-2012 |
20120040897 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES - A compound of formula (I) or a tautomeric form, regioisomer, stereoisomer, solvate, N-oxide or pharmaceutically acceptable salts thereof; wherein ‘a’—is selected from the group consisting of substituted or unsubstituted heterocycloalkyl ring and substituted or unsubstituted carbohydrate moiety y is a member selected from —O—, —CO—, —S02-, aminoalkyl or formula (II) wherein, R | 02-16-2012 |
20120040898 | PHARMACEUTICAL COMPOSITIONS - A pharmaceutical composition comprising a combination of
| 02-16-2012 |
20120058941 | GLUCOPYRANOSIDE COMPOUND - A compound of the formula: | 03-08-2012 |
20120058942 | METHODS FOR CONTROLLING BLOOD-GLUCOSE LEVELS IN INSULIN-REQUIRING SUBJECTS - The present invention relates to methods of controlling blood glucose levels in subjects receiving an insulin therapy. The methods include administering to the subject receiving an insulin therapy a dipeptidyl peptidase inhibitor and a GLP-1 related peptide. The present invention relates also to the use of such a combination for treating insulin-requiring diabetes mellitus and conditions related thereto. | 03-08-2012 |
20120083443 | Control of ATP Release by Red Blood Cells and Therapeutic Applications Thereof - The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCS treated with insulin accumulate significantly less cAMP and release significantly less ATP than normal RBCS. Likewise, RBCS of patients suffering from type 2 diabetes (hyperinsulinemia) accumulate significantly less cAMP and release significantly less ATP than normal RBCS. It was further discovered that prostaglandin analogues synergistically work with phosphodiesterase 3B inhibitors to improve or increase cAMP accumulation and ATP release RBCS. Thus the invention is directed to compositions and methods for improving ATP release by RBCS, via administering PDE3B inhibitor or a combination of PDE3B inhibitor and prostaglandin analogue. | 04-05-2012 |
20120101033 | RETINITIS PIGMENTOSA TREATMENT - A method of treatment of retinitis pigmentosa using a medically effective dose of insulin, IGF-1, and chlorin e6 topically applied to the conjunctival sac of the afflicted eye. The combination of these is very effective in treating retinitis pigmentosa and may be repeated as directed by a medical practitioner. The method includes preparing the dosage and filling an eye dropper with the compound, then having the patient lie in a supine position while administering the dosage. The patient remains in this position for 5 minutes to ensure absorption of the compound. In one embodiment, single use eye droppers are provided to simplify treatment. The particular dosage is adjusted to take individual metabolisms into account. A thorough examination of the patient's eyes should be done prior to treatment. | 04-26-2012 |
20120108505 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE - The present invention relates to compounds of the general formula (I): wherein R | 05-03-2012 |
20120122776 | DPP-IV INHIBITORS FOR TREATMENT OF DIABETES IN PEDIATRIC PATIENTS - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in paediatric patients. | 05-17-2012 |
20120129769 | ORALLY ADMINISTERABLE PHARMACEUTICAL PREPARATION CONTAINING INSULIN - The subject of the invention is an orally administerable pharmaceutical preparation containing a combination of biotechnologically produced human recombinant insulin and/or modified insulin or an analogue and/or derivative thereof, a protease inhibitor and a high molecular weight (natural) protein. The invention relates to a method for the production of the pharmaceutical preparation as well. The subject of the invention also covers the use of the pharmaceutical preparation and a method for the treatment of diabetes in mammals. | 05-24-2012 |
20120149637 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 06-14-2012 |
20120157377 | METHODS TO ENHANCE NIGHT VISION AND TREATMENT OF NIGHT BLINDNESS - The invention is for a safe and effective method of administering an opthalmological therapeutic agent for the treatment of night blindness and improving night vision, using insulin, and chlorin e6, preparations instilled into the conjunctival sac as ophthalmic drops. Night blindness and decreased night vision is associated with retinal diseases such as dry age related macular degeneration, retinitis pigmentosa and other such related eye diseases by using insulin, chlorin e6, ketamine, and monoclonal antibodies and IGF-1. The ophthalmic preparations may be supplemented with oral intake of various retinal photoreceptors vision supporting lutein, vitamin A, Zeaxanthin, Omega 3 Oils and other nurticeuticals. They may also be supplemented with cholesterol lowering statins in the elderly with high blood cholesterol to prevent eye diseases such as AMD contributing to night vision and night blindness. | 06-21-2012 |
20120178676 | PEGYLATED C-PEPTIDE - The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo. | 07-12-2012 |
20120178677 | SOFT PROTEASE INHIBITORS, AND PRO-SOFT FORMS THEREOF - The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. Another aspect of the invention provides for the use of the disclosed compounds for treating Type II diabetes, insulin resistance, glucose intolerance, hyperglycemia, hypoglycemia, hyperinsulinemia, obesity, hyperlipidemia, or hyperlipoproteinemia. | 07-12-2012 |
20120178678 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS - The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: —R | 07-12-2012 |
20120178679 | FUSED AROMATIC PTP-IB INHIBITORS - The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes. | 07-12-2012 |
20120178680 | GLYCOSIDE DERIVATIVES AND USES THEREOF - This invention relates to compounds represented by formula (I): | 07-12-2012 |
20120178681 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT - Bipiperidinyl compounds of the formula I, are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. | 07-12-2012 |
20120184489 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L | 07-19-2012 |
20120196801 | Wound-healing, anti-ambustial, regenerating, and anti-viral pharmaceutical formula for local administration - The main active ingredients of the formula are papaverin, bendazol, and insulin. The drug may be produced in soft, liquid medicinal form or as an aerosol. | 08-02-2012 |
20120214736 | COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS - The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein. | 08-23-2012 |
20120225812 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF - The present invention provides substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. | 09-06-2012 |
20120245085 | Pharmaceutical Solution of Non Covalently Bound Albumin and Acylated Insulin - If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection. | 09-27-2012 |
20120252725 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS - The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease. | 10-04-2012 |
20120258913 | GLUCOPYRANOSIDE COMPOUND - A compound of the formula: | 10-11-2012 |
20120270778 | Compositions and Methods for Non-Invasive Treatment of Chronic Complications of Diabetes - The present invention provides C-peptide compositions that permit the noninvasive or non-injectable administration of C-peptide via nasal or pulmonary routes, as well as methods for treating disease. | 10-25-2012 |
20120277150 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | 11-01-2012 |
20120283181 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME - Physical crystal structures of a compound of the formula I: | 11-08-2012 |
20120295846 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE - A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate. | 11-22-2012 |
20120322727 | Pharmaceutical Compositions for Intranasal Administration for the Treatment of Neurodegenerative Disorders - In one embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In yet another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions of the invention may be used to treat or prevent a neurodegenerative disorder such as Alzheimer's disease, stroke, Parkinson's disease, multiple sclerosis, spinal cord injuries, and/or traumatic brain injuries and the like, in addition to other systemic and local diseases. | 12-20-2012 |
20130005650 | Methods and compositions for treating diseases associated with pathogenic proteins - Methods and compositions are provided comprising acriflavine for inhibiting and treating diseases and disorders associated with pathogenic proteins causing neurodegenerative diseases and amyloid diseases, such as protease resistant prion proteins (PrP | 01-03-2013 |
20130012434 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE - The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto. | 01-10-2013 |
20130017993 | GLYCOSIDE DERIVATIVES AND USES THEREOF - This invention relates to compounds represented by formula (I): | 01-17-2013 |
20130053308 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS - New 4-amino-pyrimidine derivatives as potent antagonists of the adenosine Aza receptor formula (I): (I) The invention provides as well a method for preparing such compounds, pharmaceutical compositions comprising an effective amount of these compounds and the use of such compounds in the manufacture of a medicament to treat pathological affections that can be improved by antagonism of the adenosine Aza receptor. | 02-28-2013 |
20130059777 | MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION - Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders. | 03-07-2013 |
20130079279 | PHARMACEUTICAL COMPOSITION COMPRISING AVE0010 AND INSULIN GLARGINE - Subject of the present invention is A pharmaceutical composition comprising (a) desPro | 03-28-2013 |
20130109620 | BALAGLITAZONE COMPOSITIONS AND METHODS | 05-02-2013 |
20130123172 | Treatment of Type 2 Diabetes With FTY720 - The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog. | 05-16-2013 |
20130130974 | NOVEL SYNTHETIC APPROACH TO beta-AMINOBUTYRYL SUBSTITUTED COMPOUNDS - The present invention relates to process to prepare β-aminobutyryl compounds having β-amino acid core structural moieties and optionally having γ-phenyl and/or heterocyclic structural moieties. Such compounds are useful as key structure framework of modern drug chemistry. | 05-23-2013 |
20130150292 | Soft Protease Inhibitors and Pro-Soft Forms Thereof - The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 06-13-2013 |
20130157940 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 06-20-2013 |
20130157941 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances. | 06-20-2013 |
20130165372 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 06-27-2013 |
20130172248 | 3-[4-(PHENYLAMINOOXALYLAMINO)PHENYL]HEX-4-YNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT - The invention relates to 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, and to physiologically compatible salts thereof. | 07-04-2013 |
20130172249 | PURINE COMPOUNDS AS PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS, THEIR PROCESS AND MEDICINAL APPLICATIONS - The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. | 07-04-2013 |
20130178415 | Injectable solution at pH 7 comprising at least one basal insulin the PI of which is between 5.8 and 8.5 and a substituted co-polyamino acid - A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone. | 07-11-2013 |
20130184204 | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions - The present invention relates to substituted quinazolines of formula (I): | 07-18-2013 |
20130210717 | GENE THERAPY FOR DIABETES WITH CHITOSAN-DELIVERED PLASMID ENCODING GLUCAGON-LIKE PEPTIDE 1 - Chitosan delivers a plasmid encoding Glucagon-Like Peptide 1 (GLP-1) to cells in a patient for gene therapy of diabetes. Chitosan is optimized for plasmid transfection by modulating three of its physico-chemical properties: degree of deacetylation (DDA), molecular weight (MW), and ratio of amines on chitosan to phosphates on DNA (N:P ratio), Chitosan 92-10-5 (DDA-MW-N:P) is more efficient than chitosans 80-10-10 and 80-80-5 in delivering a plasmid encoding luciferase or GLP-1(7-37) to cells. In the Zucker Diabetic Fatty (ZDF) rat model of diabetes, chitosan-delivered pVax plasmid encoding GLP-1 lowers glucose levels, increases insulin production and reduces weight gain. | 08-15-2013 |
20130210718 | Biomarkers for Cardiodiabetes - The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes. | 08-15-2013 |
20130210719 | TREATMENT OF HEART FAILURE - The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof. | 08-15-2013 |
20130210720 | TREATMENT OF HEART FAILURE - The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof. | 08-15-2013 |
20130210721 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | 08-15-2013 |
20130231282 | METHODS FOR ADMINISTERING HYPOGLYCEMIC AGENTS - The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists. | 09-05-2013 |
20130252885 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST - The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them. | 09-26-2013 |
20130252886 | METHODS OF DELAYING AND TREATING DIABETES - The present invention provides methods of treating hyperglycemia and delaying the onset of diabetes, comprising administering to a mammal in need thereof a therapeutically effective amount of a GABA receptor agonist at or near a time of an exogenous insulin administration or a meal. | 09-26-2013 |
20130274184 | ER STRESS RELIEVERS IN BETA CELL PROTECTION - The present invention is based on the discovery that certain small molecules can relieve ER stress, leading to increased insulin production in beta cells and improved insulin secretion. Methods of treating a disease or disorder in a subject, wherein the disease or disorder is characterized by intracellular endoplasmic reticulum (ER) stress, by administering to the subject, an effective amount of a compound that is an ER stress reliever, are provided herein. | 10-17-2013 |
20130281365 | FUSED AROMATIC PTP-1B INHIBITORS - The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes. | 10-24-2013 |
20130281366 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA - The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 10-24-2013 |
20130296236 | TREATMENT PROTOCOL OF DIABETES TYPE 2 - The present invention refers to a treatment protocol for diabetes type 2 patients. | 11-07-2013 |
20130296237 | Use Of Chloroquine To Treat Metabolic Syndrome - The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption. | 11-07-2013 |
20130303446 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The invention relates to a pharmaceutical combination comprising the compound of formula I | 11-14-2013 |
20130310312 | COMBINATION OF INSULIN WITH TRIAZINE DERIVATIVES AND ITS USE FOR TREATING DIABETES - The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) | 11-21-2013 |
20130316946 | EXTENDED RECOMBINANT POLYPEPTIDE-MODIFIED C-PEPTIDE - The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise modified C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo. | 11-28-2013 |
20130324464 | ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF - Disclosed are an aryl glycoside compound as represented by formula I or formular I′, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential. | 12-05-2013 |
20130331321 | PERHEXILINE FOR TREATING CHRONIC HEART FAILURE - Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin. | 12-12-2013 |
20130338066 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 12-19-2013 |
20130345124 | METHODS AND KITS FOR PREVENTING HYPOGLYCEMIA - Improved methods and kits for treating the long-term complications of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits can also maintain good glycemic control and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy. | 12-26-2013 |
20130345125 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia. | 12-26-2013 |
20130345126 | BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia. | 12-26-2013 |
20130345127 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 12-26-2013 |
20130345128 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF - The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia. | 12-26-2013 |
20140024583 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 01-23-2014 |
20140024584 | TETRASUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 01-23-2014 |
20140038889 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto - The present invention relates to the GPR119 agonist, 1-methylcyclopropyl 4-(5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidin-4-yloxy)piperidine-1-carboxylate (Compound 1): and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing the secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto. | 02-06-2014 |
20140045746 | ANTIDIABETIC TRICYCLIC COMPOUNDS - Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 02-13-2014 |
20140051629 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to the GPR119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide; -fluoro-4-(5-fluoro-6-(4-(3-(2-fluoro-propan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide; and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto. | 02-20-2014 |
20140057842 | COMPOSITIONS AND METHODS FOR CELL HOMING AND ADIPOGENESIS - Provided is a method of causing a cell to migrate to a scaffold and there differentiate to form adipose or adipose-like cells or tissue. Also provided is a method of treating a mammal that has a tissue defect. Further provided is a tissue scaffold comprising a cell homing composition and an adipogenic composition. Additionally, a method of making a tissue scaffold capable of recruiting a cell and differentiating the recruited cell to form adipose or adipose-like cells or tissue is provided. | 02-27-2014 |
20140066369 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto - The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto. | 03-06-2014 |
20140088002 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES - The present invention relates to compositions and methods for treatment and/or prevention of diabetes or pre-diabetes. In particular, the invention provides compositions and methods for the treatment and/or prevention of diabetes or pre-diabetes, based on the use of angiotensin-(1-7) peptides, functional equivalents thereof, and/or angiotensin (1-7) agonists. | 03-27-2014 |
20140107024 | Treatment of Type 2 Diabetes With FTY720 - The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog. | 04-17-2014 |
20140155322 | Method of Preventing Or Reducing Scarring Of Human Skin - Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring whilst enhancing re-epithelialisation of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and/or prevent normal and/or pathological scarring. | 06-05-2014 |
20140171363 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF - The present invention provides compounds of formula (I); | 06-19-2014 |
20140206611 | LONG-ACTING INSULIN FORMULATIONS - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 07-24-2014 |
20140206612 | ORAL INSULIN THERAPIES AND PROTOCOL - Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy. | 07-24-2014 |
20140221286 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION - It is discovered that sodium-channel blockers inhibit the secretion of glucagon from pancreatic alpha cells. The present disclosure, based on such discoveries, provides compositions and methods for the treatment of hyperglycemia and related diseases and conditions with Na-channel blockers. | 08-07-2014 |
20140243261 | Method for treating diabetes and fatty liver disese by stimulating cellular metabolism - The present invention is a method of treating various diseases and conditions through administering a substantial caloric load coupled with administration of hormone to stimulate the body to convert that caloric load and increase metabolism in at least some cells. Body functioning converts intracellular adenosine triphosphate (ATP) as a part of normal cell function. Complex control systems balance caloric inputs by managing internal hormone levels to consume, store, or eliminate various types of caloric inputs. This invention stimulates these systems to increase metabolism of cells within the body and thereby treat various diseases and conditions. Many patients find their metabolism after treatment to be in better balance, and the patient's health improved. | 08-28-2014 |
20140243262 | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 08-28-2014 |
20140249080 | Method for the early diagnosis of clinically latent placental insufficiency associated with defective placental maturation - The present invention relates to a method for the early diagnosis of a clinically latent placental insufficiency in pathological placental maturation, and the prophylaxis of an intrauterine fetal hypoxia/asphyxia at the due date or after a prolonged gestation, comprising determining the amount and/or the concentration of the biomarker prokineticin 1 (EG-VEGF) and/or its receptor PKR1 and/or PKR2 in a sample from the pregnant subject and/or the pregnancy. In a preferred embodiment, the invention is based on determining the ratio of the amount and/or the concentration of bFGF/PK1 as a measure of current functional condition and an indicator of latent clinical problems such as placental dysfunction resulting in fetal hypoxia. | 09-04-2014 |
20140256624 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to a pharmaceutical composition according to the claim | 09-11-2014 |
20140274889 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY - The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk. | 09-18-2014 |
20140274890 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin. | 09-18-2014 |
20140296141 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus - The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues. | 10-02-2014 |
20140303077 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 10-09-2014 |
20140309165 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS - The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease. | 10-16-2014 |
20140323399 | COMPOSITIONS AND METHODS FOR INCREASING INSULIN SENSITIVITY - Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin. | 10-30-2014 |
20140336112 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 11-13-2014 |
20140342981 | HEPATIC INSULIN SENSITIZING SUBSTANCE AND TEST MEAL FOR INSULIN SENSITIZATION - The present invention provides methods of treating prediabetes, hyperglycemia, type 2 diabetes, AMIS syndrome, and obesity in a subject by administering to the patient HISS. The present invention also provides methods of diagnosing AMIS syndrome in a patient. Additionally, the present invention provides a method of shifting nutrient storage in meat-producing livestock to muscle rather than fat. | 11-20-2014 |
20140349927 | Ladostigil Therapy For Immunomodulation - Methods for treating individuals suffering from inflammation, specifically systemic inflammation including septic shock and inflammatory conditions affecting the gastrointestinal, myocardial and endocrine systems with ladostigil. | 11-27-2014 |
20140357555 | NOVEL MONASCUSPURPURONES, PREPARATION PROCESS THEREOF, AND USES OF THE MONASCUSPURPURONES - The present invention relates to a novel monascuspurpurone compound of formula (I): | 12-04-2014 |
20140371141 | Insulin glargine/lixisenatide fixed ratio formulation - The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio. | 12-18-2014 |
20150051143 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS - The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives. | 02-19-2015 |
20150051144 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES - The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as hyperlipidemia and also have a beneficial effect on cholesterol. | 02-19-2015 |
20150051145 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS - The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease. | 02-19-2015 |
20150057220 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS - Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer. | 02-26-2015 |
20150087586 | PEGYLATED C-PEPTIDE - The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise conjugated C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo. | 03-26-2015 |
20150094259 | Transdermal Delivery Devices - A transdermal delivery device in the form of a transdermal delivery patch for the delivery of insulin is disclosed. The patch comprises cross-linked amidated low methoxy pectin, insulin and a transdermal transfer enhancing agent. | 04-02-2015 |
20150094260 | BUFFERED OPHTHALMIC COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries. | 04-02-2015 |
20150099696 | NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES - The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed to compounds suitable for the treatment of Disease conditions such as hyperlipidemia. | 04-09-2015 |
20150133371 | METHOD AND COMPOSITION FOR TREATING DIABETES MELLITUS - The present invention relates to a method or composition for glycemic control in a subject, which is effective for treating diabetes mellitus, comprising administering the subject with a pharmaceutical composition comprising a therapeutically effective amount of an aliphatic alcohol having a general formula of CH | 05-14-2015 |
20150133372 | METHODS AND COMPOSITIONS FOR THE INDUCTION OF HYPOTHERMIA - Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT | 05-14-2015 |
20150299118 | HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF - The invention relates to hexahydropentaleno derivatives, the preparation method and use in medicine thereof, and in particular to hexahydropentaleno derivatives or stereo-isomers or pharmaceutically acceptable salts thereof as shown in general formula (I), and to the preparation method therefor and pharmaceutical compositions comprising the derivatives, and to the use thereof as a therapeutical agent, especially as a DPP-IV inhibitor. The definition of each substituent in formula (I) is the same as the definition in the description. | 10-22-2015 |
20150335660 | Formulation for Regeneration of Bone, Cartilage, Teeth, and Periodontium and Treatment of Tumors and Cysts - The present invention provides a formulation comprising a corticosteroid and an insulin analog or pharmaceutical compositions thereof. Also provided is a formulation comprising a corticosteroid, insulin lispro and at least one organic acid or pharmaceutical compositions thereof. The present invention provides methods for stimulating bone and/or cartilage growth, for treating tendon and/or ligament damage, for stimulating hair growth and/or reducing hair loss, for stimulating growth of a tooth and/or periodontium and for treating tumors and cysts of the jaw by administering the formulations described herein. | 11-26-2015 |
20150359793 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 12-17-2015 |
20150361154 | THERAPEUTIC AGENTS, COMPOSITIONS, AND METHODS FOR GLYCEMIC CONTROL - The present invention relates in part to insulin proteins and pharmaceutical compositions having therapeutic advantages. | 12-17-2015 |
20150374794 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE - The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments. | 12-31-2015 |
20160002255 | ANTIDIABETIC BICYCLIC COMPOUNDS - Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 01-07-2016 |
20160015714 | USE OF A DPP-4 INHIBITOR IN AUTOIMMUNE DIABETES, PARTICULARLY LADA - The present invention relates to methods for treating and/or preventing autoimmune diabetes, particularly LADA, as well as diseases related or associated therewith, comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for modifying disease trajectory of autoimmune diabetes (particularly LADA). | 01-21-2016 |
20160022616 | Method for Treating a Pulmonary Disease State in Mammals by Up Regulating Indigenous in vivo Levels of Inflammatory Agents in Mammalian Cells - The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. The pharmaceutical agent is selected from the group comprising anti-bacterial agents, anti-virals, anti-fungals, anti-tumors, antihistamines, proteins, enzymes, hormones such as insulin, non-steroidal anti-inflammatories, cytokines, steroids, and nicotine. | 01-28-2016 |
20160030339 | Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins - The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine. | 02-04-2016 |
20160030373 | 2-AAA as a Biomarker and Therapeutic Agent for Diabetes - Methods for treating a glucose-related metabolic disorder (e.g., diabetes) comprising administration of 2-aminoadipic acid (2-AAA) to subjects in need thereof. Also described are methods for predicting a subject's risk of developing a glucose-related metabolic disorder, and to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder (e.g., diabetes). | 02-04-2016 |
20160038448 | THE INHIBITION OF THE TOXIC EFFECTS OF ISLET AMYLOID FORMATION BY FLURBIPROFEN AND FLURBIPROFEN DERIVATIVES - The subject invention provides a method of reducing the presence of toxic intermediates of amyloidosis from islet amyloid polypeptide (IAPP) in a patient, comprising administering a compound to the patient a compound having the structure: (Formula 1) wherein R1 and R2 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, or R1 and R2 are linked so as to form a cyclopropyl cyclobutyl, cyclopentyl, or cyclohexyl ring; wherein R3, R4, R5, R6 are each independently hydrogen, fluorine or chlorine; and wherein R7 is hydrogen, phenyl, fluorine, chlorine, bromine, hydroxyl, amine, carboxylic acid, C1-C6 alkyl carboxylate, amide, methyl, ethyl, butyl, pentyl, hexyl, or a pharmaceutically acceptable salt or ester thereof, so as to thereby reduce the presence of toxic intermediates of amyloidosis from islet amyloid polypeptide (IAPP) in the patient. | 02-11-2016 |
20160038449 | MULTI-COMPONENT PHARMACEUTICALS FOR TREATING DIABETES - Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat diabetes, and methods for preparing activated fatty acids are provided herein. | 02-11-2016 |
20160045533 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF - The present application relates to compositions comprising selenium compounds, such as 5′-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, Gamma-glutamyl-methylseleno-cysteine, a compound of Formula (I), Formula (II), or Formula (III), and combinations thereof, and methods of using the same for modulating glucose metabolism in a subject. | 02-18-2016 |
20160045579 | DIABETES TREATMENT - Methods and compositions for treating a patient who has recently developed diabetes are provided. The methods can include administering a tolerance-restoring agent to the patient and simultaneously administering intensive insulin therapy. | 02-18-2016 |
20160046560 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME - The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds. | 02-18-2016 |
20160046940 | TARGETING MICRORNAS FOR METABOLIC DISORDERS - Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds. | 02-18-2016 |
20160051501 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS - The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease. | 02-25-2016 |
20160067217 | METABOLIC SYNDROME TREATMENT - Formulations and methods of providing an orally-active anti-metabolic disease Fixed Dose Combinations (FDC) for use as personalized medicine to treat different components of the Metabolic Syndrome or Insulin resistance syndrome such as Type II diabetes, Hypertension, Hyperlipidemia and Obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of NSAIDS in general and selective Cox-2 inhibitors in particular and one or more anti-T2DM or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed. | 03-10-2016 |
20160068484 | SYNERGISTIC COMPOSITIONS - The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) | 03-10-2016 |
20160074518 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE PI OF WHICH IS BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED CO-POLYAMINO ACID - A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone. | 03-17-2016 |
20160074534 | GENE THERAPY COMPOSITION FOR USE IN DIABETES TREATMENT - New gene therapy constructions and compositions are the subject of present invention. The gene therapy compositions consist in adeno-associated vectors which jointly express insulin (Ins) and glucokinase (Gck) genes. The new gene therapy constructions are useful for treatment of diabetes either in dogs or human beings. | 03-17-2016 |
20160077079 | THE CHILDREN'S HOSPITAL OF PHILADELPHIA - Compositions and methods useful for the identification of therapeutic agents useful for the treatment of T2D are disclosed. | 03-17-2016 |
20160083380 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA - Compounds of the general formula (I), including their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds and the intermediates involved in their preparation. | 03-24-2016 |
20160089373 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY - The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk. | 03-31-2016 |
20160100617 | NUTRITIONAL COMPOSITION FOR PROMOTING GUT MICROBIOTA BALANCE AND HEALTH - Nutritional compositions are provided that comprise a fructo-oligosaccharaide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut micro biota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same. | 04-14-2016 |
20160114001 | INSULIN VITAMIN D CONJUGATES - The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone. | 04-28-2016 |
20160129087 | RAPID-ACTING INSULIN COMPOSITIONS - The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products. | 05-12-2016 |
20160136246 | Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes - The present invention relates to GLP-1 receptor agonists for use in hypoglycaemia or hypoglycaemic episodes in patients treated with insulin and/or suffering from type 1 diabetes, e.g. for reducing the number of hypoglycaemia or hypoglycaemic episodes. | 05-19-2016 |
20160152988 | COMPOSITIONS AND METHODS FOR EFFICACIOUS AND SAFE DELIVERY OF SIRNA USING SPECIFIC CHITOSAN-BASED NANOCOMPLEXES | 06-02-2016 |
20160175327 | TOMATIDINE, ANALOGS THEREOF, COMPOSITIONS COMPRISING SAME, AND USES FOR SAME | 06-23-2016 |
20160175395 | USE OF OSTEOPROTEGERIN (OPG) TO INCREASE HUMAN PANCREATIC BETA CELL SURVIVAL AND PROLIFERATION | 06-23-2016 |
20160194680 | Enzymatic Route For The Preparation Of Chiral Gamma-Aryl-Beta-Aminobutyric Acid Derivatives | 07-07-2016 |
20160199452 | Insulin glargine/lixisenatide fixed ratio formulation | 07-14-2016 |
20170231946 | CAFESTOL FOR TREATING DIABETES | 08-17-2017 |